# Celyad (CYAD)

The Market May be Plummeting But Prohost Picks are Not Biotech stocks had a strong start, but the gains disappeared in many stocks as the market demonstrated bearishness following a long-lasting rally...

Prohost Biotech

Dec 8, 2019

Let the Market Plummet But Not Our stocks

Atara Biotherapeutics ATA188 for MS Atara Biotherapeutics ( ATRA ) announced the presentation of initial efficacy data as well as updated safety results from its ongoing Phase 1 study of the firm’s pr...

Prohost Biotech

Dec 3, 2019

Atara Allogeneic Product ATA188 Will Confirm Whether EBV Infecting B Cells Could Cause a Difficult to Treat Kind of MS

Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected volatility in the stock market, we carefully reassessed each and very stock we picked for the Prohost Portfolio. C...

Prohost Biotech

Sep 17, 2019

End of the Year Decisions Part 2

We have a few small clinical stage firms in the Prohost Portfolio that were established with the goal of designing safer and more effective versions of the very promising CAR T immuno-oncology produc...

Prohost Biotech

Jan 24, 2019

Small firms developing improved CAR T immunotherapy products.

Celyad (CYAD) is still a clinical-stage biopharmaceutical company developing advanced or improved CAR-T cell-based therapies. Today, Celyad announced that the first patient has received an injection i...

Prohost Biotech

Dec 28, 2018

Why Celyad stock lost today instead of gaining on good news

Celyad (CYAD) announced an exclusive agreement with Horizon Discovery Group plc, for the use of its shRNA technology to generate Celyad’s second non-gene-edited allogeneic platform. The encouragement...

Prohost Biotech

Nov 30, 2018

About the Celyad/Horizon discovery agreement

Today, Prohost is highlighting news that could be transformative for a clinical-stage immunotherapy firm. The firm with promising news focuses on creating and developing safer and far-reaching Chimeri...

Prohost Biotech

Nov 1, 2018

Today's Highlighted news is from ...

Prohost Biotech

Oct 5, 2018

2

Celyad (CYAD) is an immuno-oncology firm, which created CAR T CELL treatments for cancers, including solid tumors. Celyad announced its consolidated financial results for the six-month period ending...

Why Celyad’s stock gained $2.30 today

Prohost Biotech

Aug 23, 2018

6m

5

The Treatment is Not A New Way as Being Stated, It is Only the Target, Which Has Been Changed Outstanding news announced that leukemia patients who relapsed after being treated with the chimeric rec...

A New Trial Demonstrates Promising Results of CAR T Targeting CD-22 for Leukemia Patients.

Prohost Biotech

Nov 21, 2017

7m

2

As expected by those who welcome good news from publicly-traded firms, the Food and Drug Administration (FDA) has given the green light to a second CART immuno-oncology product with the trade name Yes...

Gilead's CAR T Drug, Yescarta, is Approved for NHL Resisting Previous Treatments

The Week in Review #7 A lot more happened in the past week regarding improving the treatment of cancer and of other devastating diseases. This issue contains discoveries that aim at improving breakthr...

Prohost Biotech

Oct 19, 2017

New Breakthrough Immuno-Oncology Products

Prohost Biotech

Oct 9, 2017

22

Realizing the dream of approval of a small biotech’s lead drug would usually lead a small development-stage firm to either walking on the road to more achievements and growth, or walking in place doin...

Seattle Genetics Announced Impressive News as Did Celyad

Coming Soon... The Week in Review #3 Gilead Acquisition - Rallying by Association - Improving on Cancer Treatments... ...

Prohost Biotech

Oct 4, 2017

Gilead's Acquisition Effect on Other CAR-T Developers' Stocks

Prohost Letter #410 JUNE PDUFA DAYS This month, the FDA will decide on the approvals of drugs belonging to companies that Prohost has picked for investment. Usually, granting approvals rallies the sto...

Prohost Biotech

Sep 4, 2017

Prohost Letter #410

Prohost Biotech

Jun 13, 2017

11

AT ASCO CAR-T Was Created to Stay BlueBird Bio CAR-T Results Bluebird Bio (BLUE) presentation was well received at ASCO after the firm stated results demonstrating that all the 15 evaluable patients i...

Bluebird Flies Sky-High with Its CAR-T Wings

It is obvious that the CAR-T approach to cancer treatment is here to stay and to change the way cancer has been managed for decades. Attempts to improve the novel elegant procedure safety profile and...

Prohost Biotech

Jun 7, 2017

CAR-T Great News and About the Biotech Sector in General

Prohost Letter #409 ASCO The American Society of Clinical Oncology (ASCO) meeting is around the corner. The Meeting, which will begin on Friday June 2, 2017 and will end on Monday 5, 2017 will be diff...

Prohost Biotech

Jun 1, 2017

Prohost Letter #409

Novartis signed two different separate licensing agreements with two development-stage firms, Bluebird (BLUE) and Celyad (CYAD) . The signing of the agreements, enabled Novartis to license the two fir...

Prohost Biotech

May 25, 2017

Novartis Agreements with Celyad and Bluebird Bio Say a Lot

Prohost Letter #408 AT A GLANCE - Continued from the Previous Prohost Letter #408 In the Past issue #407, we picked the following firms: NEUROCRINE BIOSCIENCES (NBIX) Treating Tardive Dyskinesia CYTOM...

Prohost Biotech

May 5, 2017

Prohost Letter #408

Prohost Biotech

Apr 25, 2017